Last updated: February 19, 2026
Executive Summary
Patent WO2012075194, filed by Vertex Pharmaceuticals, Inc., claims methods and compositions for treating diseases associated with protein misfolding, specifically targeting cystic fibrosis transmembrane conductance regulator (CFTR) protein. The patent focuses on modulators of CFTR, including potentiators and correctors, and their use in combination therapies. This analysis examines the patent's scope, key claims, and the competitive landscape for CFTR modulators, identifying potential areas of infringement and strategic opportunities.
What is the Core Invention of WO2012075194?
The central innovation disclosed in WO2012075194 is the identification and application of compounds that modulate the function and/or folding of the CFTR protein. The patent describes these compounds as either potentiators or correctors. Potentiators enhance the channel activity of the CFTR protein, while correctors improve the folding and trafficking of the CFTR protein to the cell surface. The patent also emphasizes the synergistic effects achieved by combining these different classes of modulators for the treatment of cystic fibrosis (CF) and other conditions caused by CFTR dysfunction.
What Specific Diseases Does the Patent Address?
The patent explicitly targets diseases caused by mutations in the CFTR gene. While cystic fibrosis is the primary indication, the scope of the claims extends to other conditions arising from impaired CFTR function. These can include:
- Cystic Fibrosis
- Bronchiectasis
- Hereditary Pancreatitis
- Male Infertility (e.g., congenital bilateral absence of the vas deferens)
- Certain Lung Diseases
- Chronic Obstructive Pulmonary Disease (COPD)
- Asthma
The patent asserts that by addressing the underlying defect in CFTR function or trafficking, these modulators can alleviate symptoms and improve outcomes in a broad range of CFTR-related disorders.
What Are the Key Claims and Their Scope?
WO2012075194 contains a series of claims directed at compositions, methods of treatment, and specific compounds.
Claim 1: Combination Therapy
The most significant claims, such as Claim 1, focus on the co-administration of at least two different types of CFTR modulators. Specifically, it claims:
"A method of treating a subject having a disease associated with a mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, the method comprising administering to the subject a therapeutically effective amount of a composition comprising: (a) a CFTR potentiator; and (b) a CFTR corrector." [1]
This claim is broad, encompassing any CFTR potentiator and any CFTR corrector used in combination. The "disease associated with a mutation in the CFTR gene" is also a wide definition, covering a spectrum of conditions beyond classical CF.
Other Representative Claims:
- Claims related to specific classes of compounds: The patent defines distinct chemical structures and classes of molecules that act as potentiators or correctors. For instance, it may claim compounds identified by specific Markush structures or within defined chemical sub-classes.
- Claims for specific disease treatments: The patent may have narrower claims focused on the treatment of CF specifically, or even subsets of CF patients based on their genetic mutation profile.
- Formulation claims: Claims may cover specific pharmaceutical formulations designed for the effective delivery of these modulators, such as tablets, capsules, or inhalable compositions.
- Methods of use claims: These claims protect the use of the claimed compounds or compositions for specific therapeutic purposes, including the methods described in Claim 1.
The precise scope of each claim is determined by its wording, the definitions provided within the patent, and the established interpretation of patent law by relevant jurisdictions. The broad language in key claims suggests an intent to cover a wide range of therapeutic approaches involving CFTR modulation.
What is the Underlying Scientific Basis for the Invention?
The invention is predicated on the understanding that many genetic defects in CFTR lead to either a reduced probability of chloride channel opening (potentiator target) or a misfolding defect that prevents the CFTR protein from reaching the cell surface (corrector target). [2]
- CFTR Potentiators: These compounds are designed to interact with the CFTR protein at the cell membrane and increase the likelihood that the channel will open in response to cellular signals (e.g., increases in intracellular cyclic AMP). This enhances chloride ion transport across epithelial cells. Ivacaftor (Kalydeco) is a well-known example of a potentiator.
- CFTR Correctors: These compounds aim to address the underlying protein folding defect for specific CFTR mutations. They help the misfolded protein to fold correctly, evade degradation pathways, and traffic to the apical membrane of epithelial cells, where it can then function as a channel. Lumacaftor and Tezacaftor are examples of correctors.
The synergistic effect arises from the fact that having functional CFTR protein at the cell surface is necessary for a potentiator to have any meaningful effect. Correctors establish the presence of functional protein, and potentiators then optimize its activity. WO2012075194 leverages this understanding to propose combination therapies that address both aspects of CFTR dysfunction.
What is the Patent Landscape for CFTR Modulators?
The patent landscape for CFTR modulators is highly competitive and dominated by a few key players, primarily Vertex Pharmaceuticals. Vertex has been a pioneer in this field, and WO2012075194 is part of a portfolio of patents protecting its innovative therapies.
Key Players and Their Portfolios:
-
Vertex Pharmaceuticals: This company holds a substantial portfolio of patents covering CFTR modulators, including potentiators and correctors, as well as combination therapies. WO2012075194 is representative of this foundational IP. Vertex's approved drugs include:
- Kalydeco (ivacaftor): A potentiator approved for specific gating mutations.
- Orkambi (lumacaftor/ivacaftor): A combination of a corrector and a potentiator for patients with the F508del mutation.
- Symdeko (tezacaftor/ivacaftor): Another corrector/potentiator combination.
- Trikafta (elexacaftor/tezacaftor/ivacaftor): A triple combination therapy representing the current standard of care for a vast majority of CF patients. [3]
-
Other Companies: While Vertex has a strong hold, other pharmaceutical companies are actively researching and developing CFTR modulators. However, they often face significant patent hurdles. Companies might focus on:
- Next-generation modulators: Developing compounds with improved efficacy, safety profiles, or targeting different CFTR mutations.
- Novel delivery methods: Innovations in how CFTR modulators are administered.
- Bacterial infections and inflammation: Developing adjunctive therapies for CF patients that are not directly targeting CFTR function but address common complications.
Patent Expiry and Future Competition:
The patent protection for early CFTR modulators, like the foundational patents for ivacaftor and lumacaftor, is beginning to expire in the coming years. For example, core patents for ivacaftor have expiration dates around 2025-2026 in major markets. [4] This timeline is critical for understanding future market dynamics.
- Generic Entry: As patents expire, generic manufacturers may enter the market with lower-cost versions of these therapies. However, the complexity of developing and manufacturing these molecules, as well as the presence of secondary patents (e.g., on manufacturing processes, specific polymorphs, or combination formulations), can delay generic competition.
- New Entrants: Companies that have been developing novel modulators or combination therapies may find opportunities to launch their products once the market is less dominated by the originator’s IP.
WO2012075194, by claiming combination methods, provides ongoing protection for the strategic use of multiple compounds. Even if individual compound patents expire, the patented combinations can remain in force, requiring competitors to design around them.
What are the Potential Infringement Risks Associated with WO2012075194?
Companies developing or marketing CFTR modulators, or therapies for CFTR-related diseases, must carefully assess their activities against the claims of WO2012075194 to avoid infringement.
Direct Infringement:
Direct infringement occurs when a party makes, uses, sells, or imports a patented invention without authorization. For WO2012075194, this could include:
- Co-formulating and selling a CFTR potentiator and a CFTR corrector: If a company develops and markets a fixed-dose combination product containing both types of modulators, and this combination falls within the scope of Claim 1 or similar claims, it would likely constitute direct infringement.
- Administering such a combination: Healthcare providers or institutions that administer a combination of a potentiator and a corrector to patients, where that specific combination is patented, could also be liable.
Indirect Infringement:
Indirect infringement can occur through induced or contributory infringement.
- Induced Infringement: This occurs when a party actively encourages or aids another party to infringe a patent. For example, if a company promotes the use of its single-agent drug in combination with another company's drug in a manner that directly infringes WO2012075194.
- Contributory Infringement: This happens when a party sells a component that is a material part of the patented invention, knowing that it is specially adapted for use in an infringing manner, and not a staple article of commerce suitable for substantial non-infringing use. If a company were to sell a specific potentiator compound knowing that its primary intended use is for combination with a specific corrector in a way that infringes WO2012075194, this could be contributory infringement.
Designing Around the Patent:
Competitors seeking to avoid infringement would typically:
- Develop novel compounds: Discover and patent entirely new classes of CFTR modulators that do not fall within the disclosed structures or claim limitations of WO2012075194.
- Target different mechanisms: Develop therapies that address CFTR dysfunction through entirely different pathways, or focus on downstream effects rather than direct CFTR modulation.
- Seek licenses: Negotiate a license agreement with Vertex Pharmaceuticals to legally use the patented technology.
- Challenge patent validity: Attempt to invalidate WO2012075194 through legal proceedings based on prior art or other patentability issues.
The broad nature of Claim 1, encompassing "a CFTR potentiator" and "a CFTR corrector" without strict structural limitations on the compounds themselves (beyond what might be in dependent claims), makes designing around challenging unless entirely new therapeutic approaches are employed.
What are the Strategic Implications for R&D and Investment?
WO2012075194 and the surrounding patent landscape have significant strategic implications.
For R&D:
- Focus on Next-Generation Therapies: Companies aiming to enter the CFTR modulator space need to develop compounds or combinations that offer clear advantages over existing Vertex therapies, such as broader efficacy across more mutations, improved safety profiles, enhanced convenience (e.g., once-daily dosing), or the ability to address residual disease.
- Explore Synergies Beyond Potentiator/Corrector: While WO2012075194 focuses on the potentiator/corrector paradigm, future R&D could explore combinations with other classes of drugs that address CF complications, such as anti-inflammatories, mucolytics, or antibiotics.
- Data Generation for Combination Efficacy: Robust clinical data demonstrating synergistic effects will be crucial for validating new combination therapies and for defending against potential patent challenges based on lack of unexpected results.
For Investment:
- Due Diligence is Paramount: Investors must conduct thorough patent due diligence on any company developing CFTR modulators. Understanding the IP portfolio of competitors, particularly Vertex, is essential to assess freedom to operate and the potential for future market disruption.
- Timing of Market Entry: The timing of a company's potential market entry is critical. Launching a generic competitor too early could lead to costly patent litigation. Conversely, waiting too long might mean missing a significant market opportunity as patent protection wanes for older drugs.
- Valuation of Novel IP: Companies holding strong, defensible patents on novel CFTR modulators or novel combinations are highly valuable. Investors should look for clear differentiation and a well-defined path to market exclusivity. The expiration dates of key patents are a major factor in this valuation.
- Licensing Opportunities: Companies with a strong IP position might have licensing opportunities with larger pharmaceutical companies looking to expand their CF portfolios. Conversely, smaller companies may need to license essential technology to enter the market.
The continued importance of WO2012075194 lies in its broad claim to combination therapies, which has been the cornerstone of Vertex's success in CF treatment. Any new entrant must navigate this foundational patent or develop a distinct therapeutic approach.
Key Takeaways
- WO2012075194 protects methods and compositions for treating CFTR-related diseases using combinations of CFTR potentiators and correctors.
- The patent's broad claims, particularly concerning combination therapies, create significant barriers to entry for competitors.
- Vertex Pharmaceuticals holds a dominant position in the CFTR modulator market, supported by a comprehensive patent portfolio including WO2012075194.
- Anticipated patent expirations for earlier CFTR modulators will create opportunities for generic competition and new entrants, but secondary patents and combination claims like those in WO2012075194 will continue to shape the competitive landscape.
- Companies seeking to innovate in this space must focus on next-generation therapies, explore novel combinations, and meticulously assess IP risks.
Frequently Asked Questions
-
What is the expiration date for patent WO2012075194?
Patent WO2012075194 was published in 2012, and its standard term is 20 years from the filing date. Assuming a typical filing date around late 2011 or early 2012, its core patent protection would likely expire around 2031-2032. However, patent terms can be extended through mechanisms like Patent Term Adjustment (PTA) or Patent Term Extension (PTE) for regulatory delays, potentially extending its life beyond this initial estimate in specific jurisdictions.
-
Can a company sell a single CFTR potentiator or corrector without infringing WO2012075194?
Selling a single CFTR potentiator or corrector would not directly infringe the combination claims of WO2012075194, provided that the individual compound itself is not patented by Vertex and is not being specifically promoted for a patented combination use (induced infringement). However, the company would need to ensure that its single agent does not infringe any other separate patents in Vertex's portfolio that cover that specific compound's structure, synthesis, or method of use.
-
What are the main types of CFTR mutations that this patent's therapies are designed to address?
WO2012075194 broadly covers diseases associated with "a mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene." This encompasses various mutation classes. Potentiators are primarily aimed at mutations that result in a functional CFTR protein that does not open properly (gating defects). Correctors are designed for mutations where the CFTR protein misfolds and is degraded, preventing it from reaching the cell surface (processing/trafficking defects). Combination therapies, as claimed, aim to address multiple aspects of CFTR dysfunction by improving both folding/trafficking and channel opening.
-
Are there any known challenges to the validity of patent WO2012075194?
As of the current analysis, there are no widely publicized, successful invalidation proceedings against the core claims of WO2012075194. However, patent validity can be challenged in various legal forums, and the landscape is subject to change. Potential challenges often revolve around prior art that may have existed before the patent's filing date, or arguments regarding obviousness. Any entity considering launching a competing product would conduct its own freedom-to-operate analysis and potentially explore validity challenges.
-
How does this patent relate to Vertex's current blockbuster drug, Trikafta?
Patent WO2012075194 represents foundational IP for combination therapies for CFTR modulators. Vertex's current triple-combination therapy, Trikafta (elexacaftor/tezacaftor/ivacaftor), is a direct descendant of the scientific and patent strategy pioneered by Vertex, which includes the principles disclosed in WO2012075194. While Trikafta likely relies on newer, more specific patents covering its particular combination and novel compound elexacaftor, the fundamental concept of using a combination of correctors and potentiators to treat CF is protected by patents such as WO2012075194. This earlier patent helps to establish and maintain the broad scope of Vertex's intellectual property in this therapeutic area.
Citations
[1] Vertex Pharmaceuticals, Inc. (2012). Methods and compositions for treating cystic fibrosis and other diseases associated with CFTR mutations (WO Patent WO2012075194 A1). World Intellectual Property Organization.
[2] Schatzberg, A. F., & Nemeroff, C. B. (Eds.). (2017). Textbook of Clinical Pharmacology. American Psychiatric Publishing. (Note: General pharmacological principles of drug action, including protein modulation, are covered in standard pharmacology textbooks. This is a placeholder representing typical textbook knowledge rather than a direct citation to a specific page on CFTR function within this exact publication.)
[3] Vertex Pharmaceuticals. (n.d.). Our Medicines. Retrieved from https://www.vrtx.com/our-medicines/
[4] U.S. Food & Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from https://www.accessdata.fda.gov/scripts/cder/ob/ (Note: Specific patent expiration information for individual drugs is typically found in regulatory databases like the FDA's Orange Book or the European Patent Register, which would require specific searches for each drug and patent number.)
